Partnering with Lundbeck

Partnerships are a key strategic objective for Lundbeck. This objective is achieved by obtaining increased value from our existing partnerships and by actively seeking and evaluating new opportunities at all times.

Over the last decade, successful partnerships, from pre-clinical through commercial, have been one of the main contributors to our position as specialists in brain disease and experts in neuroscience research.  The importance of partnerships is recognised throughout the organisation, and we strive to continuously be the partner of choice.

Why partner with Lundbeck?

1. Fully integrated company
Lundbeck is a fully integrated company with 6,000 employees in 57 countries; we have core competencies in research, clinical development, production, marketing and sales. Partnered products have successfully been integrated into our value chain – from pre-clinical to marketed products.

2. Proven track record of developing products for the market
The majority of Lundbeck’s currently marketed products are based on successful internal innovations and external development opportunities.  As a result, are currently undertaking the biggest launch effort in Lundbeck's history, making our four new products Abilify Maintena®, Brintellix®, NortheraTM and Selincro® available to people with brain disease.

The success of our products, moving through the process of being a molecule in our pipeline to being a safe product ready to be marketed, is due to our 1,300 dedicated research and development (R&D) staff, who are skilled in development and focused on project teams. In 2014, we invested approximately 20% of our total revenue in R&D.

3. Proven track record of commercial success
Thanks to Lundbeck’s strong platform and presence in over 100 countries, we have created commercial successes for our products.  In various markets worldwide, we market pharmaceuticals for the treatment of alcohol dependence, Alzheimer’s disease, epilepsy, depression and anxiety, Huntington’s disease, Parkinson’s disease, schizophrenia and bipolar I disorder.

This success is built on a large global infrastructure for sales and marketing, with almost 3,000 employees and strong regional commercial capabilities.  Our committed commercial organisation is dedicated to bringing therapies to the patients that need them.

4. Dedicated to brain diseases
Building on our own innovations and external licensing agreements, Lundbeck has more than 70 years’ experience within brain disease.  Our R&D and commercial teams are dedicated to brain disease, and we have a strong network among key opinion leaders and specialists in psychiatry and neurology, as well as among GPs.

Our strategy is to strengthen our position as a leading company within brain disease.  Brain disease is among the greatest global burdens of disease:  the patient population is expected to increase over the coming years and the unmet medical need in this area is substantial.

5. Flexible, fast decision-making on partnerships
Lundbeck’s top management is committed to developing partnerships and has designed a process to ensure structured and fast decision-making when evaluating new partnering opportunities.

Our financial position is solid, with a strong balance sheet and cash generation, enabling continuous investment in external opportunities.

Follow these links for more details on our areas of focus, our partnering process, how we collaborate and how to contact us.




Cookie Policy
You are about to leave the website.